Entering into the US market at a time of a relapse into bad times. DJIA to possibly go sub 10,000 again. IMO the health/Bio sector is almost immune (no pun intended) to the overall market gains/losses. Though the listing will show more activity, I hesitate to predict a sharp rise in the SP until confirmed figures of sales. Of course, milesones reached from then on will no doubt boost the SP.
Just my two cents worth
Rets
